According to Wallstreetcn, the U.S. President Donald Trump administration has reached new drug pricing agreements with nine biotechnology and pharmaceutical companies, including BeiGene and Sun Pharmaceutical Industries Ltd., under which the companies will offer outpatient drug discounts to state Medicaid plans so states pay prices aligned with what the participating drugmakers charge abroad; participation in state Medicaid plans is voluntary.